In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
The new oxazolidinone antimicrobial agents U100592 and U100766 demonstrated good in vitro inhibitory activity against clinical strains of Staphylococcus aureus and Staphylococcus epidermidis regardless of methicillin susceptibility. Both agents appeared bacteriostatic by time-kill analysis. Stable resistance to low multiples of the MIC of either drug could be produced only in methicillin-resistant S. aureus.
Kaatz
G W
GW
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan 48201, USA. us00167/interramp.com
Seo
S M
SM
D000081:Acetamides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D000069349:Linezolid; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D009254:Nafcillin / Q000494:pharmacology; D010080:Oxazoles / Q000494:pharmacology*; D023303:Oxazolidinones; D010406:Penicillins / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000187:drug effects*; D013212:Staphylococcus epidermidis / Q000187:drug effects*; D013997:Time Factors; D014640:Vancomycin / Q000494:pharmacology
D000081:Acetamides; D000900:Anti-Bacterial Agents; D010080:Oxazoles; D023303:Oxazolidinones; D010406:Penicillins; D009254:Nafcillin; D014640:Vancomycin; C098011:eperezolid; D000069349:Linezolid